Brain, behavior and the journey towards neuroepigenetic therapeutics

• Published in: Epigenomics Vol. 11; no. 8; pp. 969 - 981
• Main Authors: Wani, Ab Latif, Shadab, Gg Hammad Ahmad
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-06-2019
• Subjects: behavior; Brain; Brain research; Breast cancer; Cell cycle; Chromatin; Deoxyribonucleic acid; disease; DNA; DNA methylation; Drug development; Drugs; Epigenetics; Genes; Genomes; Genomics; Mental disorders; MicroRNAs; Neurogenesis; Organisms; Prostate cancer; therapeutics; therapeutics; disease; behavior; drugs; epigenetics
• ISSN: 1750-1911; 1750-192X
• DOI: 10.2217/epi-2018-0014

Epigenetics has brought about a major shift in our understanding of biological mechanisms and their associated health effects. Strong epigenetic components have been found to be involved in the progression of many diseases. In several human diseases, including debilitating psychiatric disorders, altered epigenetic status has been found as one of the main causes. With continuous progress on drug development, researchers are enthusiastic toward epigenetic therapeutics which could possibly reverse epigenetic modifications. In this article certain developments in epigenetic therapeutics are highlighted, the indiscriminate use of which could also be associated with potential risk. These risks may partly be due to our limited knowledge on genes and the mechanisms underlying epigenetic involvement in different diseases. Epigenetic changes are fundamentally important for a large number of bodily functions; nonspecific usage of therapeutics could be potentially harmful therefore there is a need to harness epigenetics positively.